Review



next generation target site amplicon sequencing service  (Azenta)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Azenta next generation target site amplicon sequencing service
    Selected sgRNA target sites are indicated, along with <t>Amplicon-EZ</t> (Genewiz) indel plots and estimated mutagenesis rates. Red arrows indicate CRISPR-generated indel peaks. Grey asterisks indicate naturally-occurring indels. Mutagenesis rates are approximated for plots in which naturally occurring indels confounded automatic rate estimation.
    Next Generation Target Site Amplicon Sequencing Service, supplied by Azenta, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/next generation target site amplicon sequencing service/product/Azenta
    Average 86 stars, based on 1 article reviews
    next generation target site amplicon sequencing service - by Bioz Stars, 2026-05
    86/100 stars

    Images

    1) Product Images from "Validated CRISPR/Cas9 guide RNAs targeting neurodevelopmental genes in the tunicate Ciona robusta"

    Article Title: Validated CRISPR/Cas9 guide RNAs targeting neurodevelopmental genes in the tunicate Ciona robusta

    Journal: bioRxiv

    doi: 10.64898/2026.03.25.711585

    Selected sgRNA target sites are indicated, along with Amplicon-EZ (Genewiz) indel plots and estimated mutagenesis rates. Red arrows indicate CRISPR-generated indel peaks. Grey asterisks indicate naturally-occurring indels. Mutagenesis rates are approximated for plots in which naturally occurring indels confounded automatic rate estimation.
    Figure Legend Snippet: Selected sgRNA target sites are indicated, along with Amplicon-EZ (Genewiz) indel plots and estimated mutagenesis rates. Red arrows indicate CRISPR-generated indel peaks. Grey asterisks indicate naturally-occurring indels. Mutagenesis rates are approximated for plots in which naturally occurring indels confounded automatic rate estimation.

    Techniques Used: Amplification, Mutagenesis, CRISPR, Generated

    Selected sgRNA target sites are indicated, along with Amplicon-EZ (Genewiz) indel plots and estimated mutagenesis rates. Red arrows indicate CRISPR-generated indel peaks. Grey asterisks indicate naturally-occurring indels. Mutagenesis rates are approximated for plots in which naturally occurring indels confounded automatic rate estimation.
    Figure Legend Snippet: Selected sgRNA target sites are indicated, along with Amplicon-EZ (Genewiz) indel plots and estimated mutagenesis rates. Red arrows indicate CRISPR-generated indel peaks. Grey asterisks indicate naturally-occurring indels. Mutagenesis rates are approximated for plots in which naturally occurring indels confounded automatic rate estimation.

    Techniques Used: Amplification, Mutagenesis, CRISPR, Generated

    All sgRNA target sequences tested in this study, along with predicted efficacy scores from CRISPOR, namely Doench ‘16 and Doench Ruleset 3 (RS3). Norm. ‘16 and Norm. RS3 represents normalized Doench ‘16 and Doench RS3 scores, in which the represented ranges (not absolute theoretical score ranges) are converted to a scale from 0 to 1. Norm+Ave = normalized Doench ‘16 and RS3 scores averaged. Mut. % = mutagenesis efficacy as measured by Amplicon-EZ sequencing. Mut. % scores in blue represent efficacies estimated from size of indel peak, and not the automated efficacies as given by automated Amplicon-EZ analysis (black Mut. % scores).
    Figure Legend Snippet: All sgRNA target sequences tested in this study, along with predicted efficacy scores from CRISPOR, namely Doench ‘16 and Doench Ruleset 3 (RS3). Norm. ‘16 and Norm. RS3 represents normalized Doench ‘16 and Doench RS3 scores, in which the represented ranges (not absolute theoretical score ranges) are converted to a scale from 0 to 1. Norm+Ave = normalized Doench ‘16 and RS3 scores averaged. Mut. % = mutagenesis efficacy as measured by Amplicon-EZ sequencing. Mut. % scores in blue represent efficacies estimated from size of indel peak, and not the automated efficacies as given by automated Amplicon-EZ analysis (black Mut. % scores).

    Techniques Used: Mutagenesis, Amplification, Sequencing

    A) Selected Tyrosinase sgRNA target sites are indicated, along with Amplicon-EZ (Genewiz) indel plots and estimated mutagenesis rates. Mutagenesis rates are approximated for plots in which naturally occurring indels confounded automatic rate estimation. B) Left: diagram of simple pigmentation assay (see text for details). Right: results of pigmentation assay of Tyr CRISPR larvae using sgRNAs 1.185 and 5.16 together (40 µg each) in combination with 50 µg Sox1/2/3>Cas9::Geminin Nterminus . ( ; ). CRISPR larvae (n = 45) were compared to negative control larvae (n = 29) electroporated with 80 µg of the “control” sgRNA plasmid instead . Plasmid DNA amounts indicated per 700 µl of total electroporation volume. Statistical significance determined using Fisher’s exact test. C) Selected VAChT sgRNA target sites indicated, along with indel plots. Dashed red line indicates alternative splicing of first exon with remaining exons encoding choline acetyltransferase (ChAT) out of view, as part of a conserved cholinergic locus. Red arrows indicate CRISPR-generated indel peaks. Grey asterisks indicate naturally-occurring indels.
    Figure Legend Snippet: A) Selected Tyrosinase sgRNA target sites are indicated, along with Amplicon-EZ (Genewiz) indel plots and estimated mutagenesis rates. Mutagenesis rates are approximated for plots in which naturally occurring indels confounded automatic rate estimation. B) Left: diagram of simple pigmentation assay (see text for details). Right: results of pigmentation assay of Tyr CRISPR larvae using sgRNAs 1.185 and 5.16 together (40 µg each) in combination with 50 µg Sox1/2/3>Cas9::Geminin Nterminus . ( ; ). CRISPR larvae (n = 45) were compared to negative control larvae (n = 29) electroporated with 80 µg of the “control” sgRNA plasmid instead . Plasmid DNA amounts indicated per 700 µl of total electroporation volume. Statistical significance determined using Fisher’s exact test. C) Selected VAChT sgRNA target sites indicated, along with indel plots. Dashed red line indicates alternative splicing of first exon with remaining exons encoding choline acetyltransferase (ChAT) out of view, as part of a conserved cholinergic locus. Red arrows indicate CRISPR-generated indel peaks. Grey asterisks indicate naturally-occurring indels.

    Techniques Used: Amplification, Mutagenesis, CRISPR, Negative Control, Control, Plasmid Preparation, Electroporation, Alternative Splicing, Generated

    Plots comparing predicted efficacy scores (Doench ‘16, Doench Ruleset 3/RS3, or normalized/averaged Doench scores) to actual mutagenesis efficacies as measured/estimated by Amplicon-EZ sequencing. All data according to the table in . Pearson’s correlations calculated and shown for each set of predictions.
    Figure Legend Snippet: Plots comparing predicted efficacy scores (Doench ‘16, Doench Ruleset 3/RS3, or normalized/averaged Doench scores) to actual mutagenesis efficacies as measured/estimated by Amplicon-EZ sequencing. All data according to the table in . Pearson’s correlations calculated and shown for each set of predictions.

    Techniques Used: Mutagenesis, Amplification, Sequencing



    Similar Products

    next generation target site amplicon sequencing service  (Azenta)
    86
    Azenta next generation target site amplicon sequencing service
    Selected sgRNA target sites are indicated, along with <t>Amplicon-EZ</t> (Genewiz) indel plots and estimated mutagenesis rates. Red arrows indicate CRISPR-generated indel peaks. Grey asterisks indicate naturally-occurring indels. Mutagenesis rates are approximated for plots in which naturally occurring indels confounded automatic rate estimation.
    Next Generation Target Site Amplicon Sequencing Service, supplied by Azenta, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/next generation target site amplicon sequencing service/product/Azenta
    Average 86 stars, based on 1 article reviews
    next generation target site amplicon sequencing service - by Bioz Stars, 2026-05
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    Selected sgRNA target sites are indicated, along with Amplicon-EZ (Genewiz) indel plots and estimated mutagenesis rates. Red arrows indicate CRISPR-generated indel peaks. Grey asterisks indicate naturally-occurring indels. Mutagenesis rates are approximated for plots in which naturally occurring indels confounded automatic rate estimation.

    Journal: bioRxiv

    Article Title: Validated CRISPR/Cas9 guide RNAs targeting neurodevelopmental genes in the tunicate Ciona robusta

    doi: 10.64898/2026.03.25.711585

    Figure Lengend Snippet: Selected sgRNA target sites are indicated, along with Amplicon-EZ (Genewiz) indel plots and estimated mutagenesis rates. Red arrows indicate CRISPR-generated indel peaks. Grey asterisks indicate naturally-occurring indels. Mutagenesis rates are approximated for plots in which naturally occurring indels confounded automatic rate estimation.

    Article Snippet: In all, 25 sgRNAs targeting the 8 genes were tested by a standard, commercially available Illumina-based, next-generation target site amplicon sequencing service (Amplicon-EZ by Genewiz) as previously described ( ).

    Techniques: Amplification, Mutagenesis, CRISPR, Generated

    Selected sgRNA target sites are indicated, along with Amplicon-EZ (Genewiz) indel plots and estimated mutagenesis rates. Red arrows indicate CRISPR-generated indel peaks. Grey asterisks indicate naturally-occurring indels. Mutagenesis rates are approximated for plots in which naturally occurring indels confounded automatic rate estimation.

    Journal: bioRxiv

    Article Title: Validated CRISPR/Cas9 guide RNAs targeting neurodevelopmental genes in the tunicate Ciona robusta

    doi: 10.64898/2026.03.25.711585

    Figure Lengend Snippet: Selected sgRNA target sites are indicated, along with Amplicon-EZ (Genewiz) indel plots and estimated mutagenesis rates. Red arrows indicate CRISPR-generated indel peaks. Grey asterisks indicate naturally-occurring indels. Mutagenesis rates are approximated for plots in which naturally occurring indels confounded automatic rate estimation.

    Article Snippet: In all, 25 sgRNAs targeting the 8 genes were tested by a standard, commercially available Illumina-based, next-generation target site amplicon sequencing service (Amplicon-EZ by Genewiz) as previously described ( ).

    Techniques: Amplification, Mutagenesis, CRISPR, Generated

    All sgRNA target sequences tested in this study, along with predicted efficacy scores from CRISPOR, namely Doench ‘16 and Doench Ruleset 3 (RS3). Norm. ‘16 and Norm. RS3 represents normalized Doench ‘16 and Doench RS3 scores, in which the represented ranges (not absolute theoretical score ranges) are converted to a scale from 0 to 1. Norm+Ave = normalized Doench ‘16 and RS3 scores averaged. Mut. % = mutagenesis efficacy as measured by Amplicon-EZ sequencing. Mut. % scores in blue represent efficacies estimated from size of indel peak, and not the automated efficacies as given by automated Amplicon-EZ analysis (black Mut. % scores).

    Journal: bioRxiv

    Article Title: Validated CRISPR/Cas9 guide RNAs targeting neurodevelopmental genes in the tunicate Ciona robusta

    doi: 10.64898/2026.03.25.711585

    Figure Lengend Snippet: All sgRNA target sequences tested in this study, along with predicted efficacy scores from CRISPOR, namely Doench ‘16 and Doench Ruleset 3 (RS3). Norm. ‘16 and Norm. RS3 represents normalized Doench ‘16 and Doench RS3 scores, in which the represented ranges (not absolute theoretical score ranges) are converted to a scale from 0 to 1. Norm+Ave = normalized Doench ‘16 and RS3 scores averaged. Mut. % = mutagenesis efficacy as measured by Amplicon-EZ sequencing. Mut. % scores in blue represent efficacies estimated from size of indel peak, and not the automated efficacies as given by automated Amplicon-EZ analysis (black Mut. % scores).

    Article Snippet: In all, 25 sgRNAs targeting the 8 genes were tested by a standard, commercially available Illumina-based, next-generation target site amplicon sequencing service (Amplicon-EZ by Genewiz) as previously described ( ).

    Techniques: Mutagenesis, Amplification, Sequencing

    A) Selected Tyrosinase sgRNA target sites are indicated, along with Amplicon-EZ (Genewiz) indel plots and estimated mutagenesis rates. Mutagenesis rates are approximated for plots in which naturally occurring indels confounded automatic rate estimation. B) Left: diagram of simple pigmentation assay (see text for details). Right: results of pigmentation assay of Tyr CRISPR larvae using sgRNAs 1.185 and 5.16 together (40 µg each) in combination with 50 µg Sox1/2/3>Cas9::Geminin Nterminus . ( ; ). CRISPR larvae (n = 45) were compared to negative control larvae (n = 29) electroporated with 80 µg of the “control” sgRNA plasmid instead . Plasmid DNA amounts indicated per 700 µl of total electroporation volume. Statistical significance determined using Fisher’s exact test. C) Selected VAChT sgRNA target sites indicated, along with indel plots. Dashed red line indicates alternative splicing of first exon with remaining exons encoding choline acetyltransferase (ChAT) out of view, as part of a conserved cholinergic locus. Red arrows indicate CRISPR-generated indel peaks. Grey asterisks indicate naturally-occurring indels.

    Journal: bioRxiv

    Article Title: Validated CRISPR/Cas9 guide RNAs targeting neurodevelopmental genes in the tunicate Ciona robusta

    doi: 10.64898/2026.03.25.711585

    Figure Lengend Snippet: A) Selected Tyrosinase sgRNA target sites are indicated, along with Amplicon-EZ (Genewiz) indel plots and estimated mutagenesis rates. Mutagenesis rates are approximated for plots in which naturally occurring indels confounded automatic rate estimation. B) Left: diagram of simple pigmentation assay (see text for details). Right: results of pigmentation assay of Tyr CRISPR larvae using sgRNAs 1.185 and 5.16 together (40 µg each) in combination with 50 µg Sox1/2/3>Cas9::Geminin Nterminus . ( ; ). CRISPR larvae (n = 45) were compared to negative control larvae (n = 29) electroporated with 80 µg of the “control” sgRNA plasmid instead . Plasmid DNA amounts indicated per 700 µl of total electroporation volume. Statistical significance determined using Fisher’s exact test. C) Selected VAChT sgRNA target sites indicated, along with indel plots. Dashed red line indicates alternative splicing of first exon with remaining exons encoding choline acetyltransferase (ChAT) out of view, as part of a conserved cholinergic locus. Red arrows indicate CRISPR-generated indel peaks. Grey asterisks indicate naturally-occurring indels.

    Article Snippet: In all, 25 sgRNAs targeting the 8 genes were tested by a standard, commercially available Illumina-based, next-generation target site amplicon sequencing service (Amplicon-EZ by Genewiz) as previously described ( ).

    Techniques: Amplification, Mutagenesis, CRISPR, Negative Control, Control, Plasmid Preparation, Electroporation, Alternative Splicing, Generated

    Plots comparing predicted efficacy scores (Doench ‘16, Doench Ruleset 3/RS3, or normalized/averaged Doench scores) to actual mutagenesis efficacies as measured/estimated by Amplicon-EZ sequencing. All data according to the table in . Pearson’s correlations calculated and shown for each set of predictions.

    Journal: bioRxiv

    Article Title: Validated CRISPR/Cas9 guide RNAs targeting neurodevelopmental genes in the tunicate Ciona robusta

    doi: 10.64898/2026.03.25.711585

    Figure Lengend Snippet: Plots comparing predicted efficacy scores (Doench ‘16, Doench Ruleset 3/RS3, or normalized/averaged Doench scores) to actual mutagenesis efficacies as measured/estimated by Amplicon-EZ sequencing. All data according to the table in . Pearson’s correlations calculated and shown for each set of predictions.

    Article Snippet: In all, 25 sgRNAs targeting the 8 genes were tested by a standard, commercially available Illumina-based, next-generation target site amplicon sequencing service (Amplicon-EZ by Genewiz) as previously described ( ).

    Techniques: Mutagenesis, Amplification, Sequencing